KYNB KYNTRA BIO, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 921299 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY104.5%
TTM net income YoY-108.0%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—
Margins
Gross margin5.6%
Operating margin-1,089.4%
Net margin-326.0%
FCF margin-913.7%
EBITDA margin-1,089.4%
Returns
ROE—
ROA-18.6%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets114.7%
Debt / equity—
Current ratio1.16x
Interest coverage-6.53x
Cash quality & payout
Operating cash flow / net income2.80x
Accruals ratio33.5%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.44M | $29.62M |
| Cost of revenue | $556,000 | $15.56M |
| Gross profit | $5.88M | $14.06M |
| R&D expense | $23.52M | $95.69M |
| SG&A expense | $27.71M | $49.33M |
| Operating income | -$45.90M | -$150.42M |
| Interest expense | $8.76M | $8.25M |
| Pretax income | -$58.29M | -$153.37M |
| Income tax | -$90,000 | -$269,000 |
| Net income | $183.45M | -$47.58M |
| EBITDA | -$45.18M | -$147.76M |
| EPS (basic) | 45.37 | -11.89 |
| EPS (diluted) | 45.37 | -11.89 |
| Weighted avg. shares (diluted) | 4.04M | 4.00M |
| Balance sheet | ||
| Cash & equivalents | $47.87M | $50.48M |
| Short-term investments | $41.11M | $0 |
| Receivables | $216,000 | $481,000 |
| Inventory | $3.74M | $3.15M |
| Current assets | $99.07M | $196.51M |
| PP&E, net | — | $0 |
| Total assets | $119.59M | $214.53M |
| Current liabilities | $29.24M | $133.31M |
| Total liabilities | $115.12M | $398.16M |
| Shareholders' equity | -$30.04M | -$225.60M |
| Shares outstanding | 4.05M | 4.04M |
| Cash flow statement | ||
| Operating cash flow | -$4.77M | -$138.00M |
| Capital expenditure | $38,000 | $266,000 |
| Free cash flow | -$4.81M | -$138.26M |
| Investing cash flow | $35.42M | $125.99M |
| Financing cash flow | -$86.03M | -$255,000 |
| Depreciation & amortization | $713,000 | $2.65M |
| Stock-based compensation | $6.58M | $25.21M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.